Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO)

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions
Carcinologic Ear, Nose, and Throat (ENT) Surgery
Interventions
DRUG

Lidocaine 20mg/ml

Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).

DRUG

Glucose 5% (placebo)

Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.

Trial Locations (2)

69004

Hospices Civils de Lyon / Hôpital de la Croix Rousse, Lyon

69008

Centre Léon Bérard, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02894710 - Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO) | Biotech Hunter | Biotech Hunter